These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

426 related items for PubMed ID: 23597716

  • 21. Incidence of pediatric invasive pneumococcal disease in the Island of Majorca (2008-2010), an area with non-universal vaccination, and estimations of serotype & children population coverage by available conjugate vaccines.
    Picazo J, Dueñas J, Ramirez A, Perez AR, Padilla E, Herrero S, Gallegos C, Culebras E, Balseiro C, Mendez C.
    BMC Infect Dis; 2013 Oct 29; 13():503. PubMed ID: 24498901
    [Abstract] [Full Text] [Related]

  • 22. The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage.
    Ciruela P, Izquierdo C, Broner S, Muñoz-Almagro C, Hernández S, Ardanuy C, Pallarés R, Domínguez A, Jané M, Catalan Working Group on Invasive Pneumococcal Disease.
    Vaccine; 2018 Nov 29; 36(50):7744-7752. PubMed ID: 30473132
    [Abstract] [Full Text] [Related]

  • 23. Pediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in Denmark.
    Harboe ZB, Valentiner-Branth P, Ingels H, Rasmussen JN, Andersen PH, Bjerre CC, Goldblatt D, Ashton L, Haston M, Konradsen HB, Lambertsen L, Danish Pneumococcal Surveillance Collaborating Group.
    PLoS One; 2013 Nov 29; 8(1):e51460. PubMed ID: 23365635
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR.
    Clin Ther; 2013 Feb 29; 35(2):119-34. PubMed ID: 23312274
    [Abstract] [Full Text] [Related]

  • 28. Antibiotic resistance and serotype distribution of invasive pneumococcal diseases before and after introduction of pneumococcal conjugate vaccine in the Kingdom of Saudi Arabia (KSA).
    Shibl AM, Memish ZA, Al-Kattan KM.
    Vaccine; 2012 Dec 31; 30 Suppl 6():G32-6. PubMed ID: 23228355
    [Abstract] [Full Text] [Related]

  • 29. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.
    Isaacman DJ, McIntosh ED, Reinert RR.
    Int J Infect Dis; 2010 Mar 31; 14(3):e197-209. PubMed ID: 19700359
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
    Ben-Shimol S, Greenberg D, Givon-Lavi N, Schlesinger Y, Somekh E, Aviner S, Miron D, Dagan R.
    Vaccine; 2014 Jun 05; 32(27):3452-9. PubMed ID: 24690148
    [Abstract] [Full Text] [Related]

  • 32. Streptococcus pneumoniae serotype distribution in Vojvodina before the introduction of pneumococcal conjugate vaccines into the National Immunization Program.
    Petrović V, Šeguljev Z, Ristić M, Djekić-Malbaša J, Radosavljević B, Medić D, Mihajlović-Ukropina M, Hadnadjev M, Gajic I, Opavski N.
    Srp Arh Celok Lek; 2016 Jun 05; 144(9-10):521-6. PubMed ID: 29653038
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children.
    van der Linden M, Weiß S, Falkenhorst G, Siedler A, Imöhl M, von Kries R.
    Vaccine; 2012 Aug 31; 30(40):5880-5. PubMed ID: 22771186
    [Abstract] [Full Text] [Related]

  • 35. Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012.
    Farnham AC, Zimmerman CM, Papadouka V, Konty KJ, Zucker JR, Nattanmai GV, Jose S, Rosen JB.
    JAMA Pediatr; 2015 Jul 31; 169(7):646-52. PubMed ID: 25938798
    [Abstract] [Full Text] [Related]

  • 36. Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination Programs.
    Shigayeva A, Rudnick W, Green K, Chen DK, Demczuk W, Gold WL, Johnstone J, Kitai I, Krajden S, Lovinsky R, Muller M, Powis J, Rau N, Walmsley S, Tyrrell G, Bitnun A, McGeer A, Toronto Invasive Bacterial Diseases Network.
    Clin Infect Dis; 2016 Jan 15; 62(2):139-47. PubMed ID: 26354970
    [Abstract] [Full Text] [Related]

  • 37. Impact of pneumococcal conjugate vaccine (PCV7 and PCV13) on pneumococcal invasive diseases in Italian children and insight into evolution of pneumococcal population structure.
    Camilli R, D'Ambrosio F, Del Grosso M, Pimentel de Araujo F, Caporali MG, Del Manso M, Gherardi G, D'Ancona F, Pantosti A, Pneumococcal Surveillance Group.
    Vaccine; 2017 Aug 16; 35(35 Pt B):4587-4593. PubMed ID: 28716556
    [Abstract] [Full Text] [Related]

  • 38. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study.
    Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW.
    Clin Infect Dis; 2009 Jul 15; 49(2):205-12. PubMed ID: 19508165
    [Abstract] [Full Text] [Related]

  • 39. Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults.
    Gladstone RA, Jefferies JM, Faust SN, Clarke SC.
    Expert Rev Vaccines; 2012 Aug 15; 11(8):889-902. PubMed ID: 23002969
    [Abstract] [Full Text] [Related]

  • 40. The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel.
    Regev-Yochay G, Katzir M, Strahilevitz J, Rahav G, Finn T, Miron D, Maor Y, Chazan B, Schindler Y, Dagan R, IAIPD group.
    Vaccine; 2017 Apr 25; 35(18):2449-2456. PubMed ID: 28342668
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.